Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
4 Reasons Why DexCom Could Be A Good Buy For 2026
DexCom, which has underperformed its medical equipment and S&P 500 peers in a big way in 2025, could be staring at better prospects next year. Stelo is facing vast and underpenetrated prediabetes and type-2 non-insulin markets, with potential international expansion likely in 2026. DXCM's solid FCF margins and cash reserves support a $750M buyback program, with 75% of authorization still available through June 2026.
DexCom (DXCM) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting started.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature businesses, exhibiting fairly steady performance from quarter to quarter.
